Nyhet från partner

AdjuTec Pharma to start phase I trial with APC148

AdjuTec Pharma to start phase I trial with APC148

Adjutec is set to start its phase I clinical trial for the enzyme inhibitor APC148, marking a significant milestone for the company.

The trial begins September 18 with CTC in Uppsala and will focus on assessing the candidate’s safety.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

Denna källa har få eller inga artiklar bakom betalvägg
Läs hela texten hos Biostock

Nyhetsbrev